NKTX Nkarta Inc

$NKTX At $1.60 Nkarta’s market cap is about $119M against roughly $207M of estimated cash. That’s about $87M below cash, or 0.58x. The pipeline is again valued at clearly less than zero.

$NKTX What fool is selling for this cheap? I’m not complaining I’m doubling down on my position at this discount.

$NKTX is anyone even on this board ..why this one still exist if no one even cares with data in a week ..

$NKTX started a position today .. hopefully it’s the right time.. let me know your thoughts folks :)

$NKTX It will hit $1.70 sooner! watching this from few weeks.. will be a great long term buy for 5x!! Took a starter at $1.93!

$NKTX Now trading at 60% of cash value. Well defined range of $1.70 to $3.70 for two years. I guess I am bullish. 🤷‍♂️

$NKTX It's actually shocking to see it this low this close to data. It's back under cash value, strong management and imo strong hints that data will be good going from previous investor events. The fact data was delayed to put out a more comprehensive results also derisks it. The market seems to be dumping pre revenue stocks and the xbi is shaky so it's unfairly being beaten down. I'm adding more as RVR at these levels it too good to miss.

$NKTX I believe we’re officially a month away from clinical data being presented at ACR. The market is undervaluing it but I’m loading up even more.

$NKTX Artiva stopped its clinical trials and still has a higher share price than this, lol. Make it make sense!

$NKTX explains the recent price weakness. Paradoxically ACR probably coming at the right time to address some of the inevitable concerns.

$NKTX Hard to understand this price level. These are the facts: • ~0.57x cash: $125M market cap vs ~$217M cash • Cash/share ~$3.0: ~70% upside to cash alone • No debt; runway into 2029 • Clean safety (25 patients): zero CRS, ICANS, GvHD, serious infections or deaths • Deep B-cell depletion plus moderate-to-major myositis responses • First CAR-NK in myositis • ARC abstracts look solid, backed by best in class scientists presenting data in 2 accepted oral talks. • NK approach already validated by Artiva (71% ACR50, Phase 3) • Partner/M&A optionality: off-the-shelf, redosable

$NKTX Abstracts are published and preliminary data are presented. Safety is the main achievement. Overall the results look really promising. The main question is the efficacy compared to existing players.

$NKTX down to $140M market cap vs $240M cash, which lasts into 2029 (don't think you can find that safe anywhere in biotech, factoring in near term data too). On top of that at a major support area going into key Nov data. I like my odds at this level when biotech turns around. In my opinion the "safest" biotechs to be in are ones that very strongly well capitalized, with long cash runways, no need to raise, and major near term data inflection points. NKTX checks all the boxes

$NKTX yep…IMO ..this is a good one …$2 is the magic area so start loading up within 5 cents plus or minus of that and you should be good

$NKTX It's a bad idea to announce the date of a potential catalyst long beforehand. It just lets people manipulate the price comfortably knowing that nothing will come out until then...

$NKTX Citadel Advisors holding 2.9m shares! they are killing with their short, using their long position to cover! i see this going under $1 regardless of their cash!

$NKTX artv just went tits up based on long term efficacy..what does that mean for $NKTX upcoming data?

$NKTX Short it on the way down before data, load up from the bottom then long it and ride the wave to $10. Is this plan?

$NKTX I’m adding more & more if the market keeps this gem at a discount added even more at $1.84